Crizotinib , ≥99% , 877399-52-5
Synonym(s):
(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine;PF 2341066;PF02341066;PF-02341066;Xalkori
CAS NO.：877399-52-5
Empirical Formula: C21H22Cl2FN5O
Molecular Weight: 450.34
MDL number: MFCD12407409
EINECS: 638-814-9
| Pack Size | Price | Stock | Quantity |
| 50MG | RMB31.20 | In Stock |
|
| 100mg | RMB39.20 | In Stock |
|
| 250MG | RMB79.20 | In Stock |
|
| 10MG | RMB103.20 | In Stock |
|
| 500mg | RMB128.80 | In Stock |
|
| 1G | RMB213.60 | In Stock |
|
| 5g | RMB1028.80 | In Stock |
|
| 25g | RMB4559.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 192 °C |
| Boiling point: | 599.2±50.0 °C(Predicted) |
| Density | 1.47±0.1 g/cm3(Predicted) |
| storage temp. | room temp |
| solubility | Soluble in DMSO (up to 25 mg/ml with warming) or in Ethanol (up to 25 mg/ml with warming) |
| pka | 9.81±0.10(Predicted) |
| form | powder |
| color | white to tan |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 2 months. |
| InChIKey | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
| SMILES | C1(N)=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@@H](C1=C(Cl)C=CC(F)=C1Cl)C |
Description and Uses
Crizotinib is an oral ALK/ROS1/MET/RON inhibitor approved by the U.S. Food and Drug Administration. Crizotinib is not only used for the treatment of ALK- or ROS1-positive metastatic non-small cell lung cancer (NSCLC), but also for the treatment of adult and paediatric patients 1 year of age and older with unresectable, relapsed or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive interstitial myofibroblastic tumours (IMT). In addition, crizotinib has preclinical efficacy in the Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs) patient cells, JAK2 mutant cell lines, and JAK2 mutant mouse models. Crizotinib is recommended for the treatment of patients with MPN, particularly in the setting of JAK inhibitor resistance[1].
Crizotinib is a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). Crizotinib is a potential antitumor agent. In August 2011, the United States FDA approved crizotinib for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC).
Safety
| Symbol(GHS) |    GHS07,GHS08,GHS09 |
| Signal word | Warning |
| Hazard statements | H317-H319-H341-H400 |
| Precautionary statements | P201-P273-P280-P302+P352-P305+P351+P338-P308+P313 |
| Safety Statements | 24/25 |
| RIDADR | UN 3077 9 / PGIII |
| WGK Germany | 3 |
| HazardClass | IRRITANT |
| HS Code | 29333990 |
